Cargando…
The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study
AIM: Continuous renal replacement therapy (CRRT) with a cytokine‐adsorbing hemofilter (CAH) is effective in the treatment of sepsis. Two filter types, namely polymethyl methacrylate (PMMA) and surface‐treated AN69 (AN69ST) hemofilters, have been successfully used for CRRT, but no direct comparisons...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328921/ https://www.ncbi.nlm.nih.gov/pubmed/30651999 http://dx.doi.org/10.1002/ams2.382 |
_version_ | 1783386732984532992 |
---|---|
author | Kobashi, Shuichi Maruhashi, Takaaki Nakamura, Tomoya Hatabayashi, Erika Kon, Akihide |
author_facet | Kobashi, Shuichi Maruhashi, Takaaki Nakamura, Tomoya Hatabayashi, Erika Kon, Akihide |
author_sort | Kobashi, Shuichi |
collection | PubMed |
description | AIM: Continuous renal replacement therapy (CRRT) with a cytokine‐adsorbing hemofilter (CAH) is effective in the treatment of sepsis. Two filter types, namely polymethyl methacrylate (PMMA) and surface‐treated AN69 (AN69ST) hemofilters, have been successfully used for CRRT, but no direct comparisons have been published to date. This study compared the efficacy, as measured by 28‐day survival rates, of PMMA and AN69ST hemofilters in patients receiving CAH‐CRRT. METHODS: This retrospective observational study reviewed the medical records of 142 patients who received CAH‐CRRT between November 2013 and February 2015. RESULTS: The 28‐day survival rates were higher in the AN69ST group than in the PMMA group for patients with or without sepsis (all patients, 79.4% versus 54.1%; patients with sepsis, 77.3% versus 50.0%; patients without sepsis, 83.3% versus 57.5%; P < 0.05). No significant differences were observed regarding 28‐day survival rates of patients with or without sepsis (AN69ST, 77.3% versus 83.3%; P = 0.51; PMMA, 50.0% versus 57.5%; P = 0.61) using the same hemofilter. CONCLUSION: The AN69ST hemofilter could be more effective than PMMA hemofilters for improving the survival outcomes of patients with or without sepsis. |
format | Online Article Text |
id | pubmed-6328921 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-63289212019-01-16 The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study Kobashi, Shuichi Maruhashi, Takaaki Nakamura, Tomoya Hatabayashi, Erika Kon, Akihide Acute Med Surg Original Articles AIM: Continuous renal replacement therapy (CRRT) with a cytokine‐adsorbing hemofilter (CAH) is effective in the treatment of sepsis. Two filter types, namely polymethyl methacrylate (PMMA) and surface‐treated AN69 (AN69ST) hemofilters, have been successfully used for CRRT, but no direct comparisons have been published to date. This study compared the efficacy, as measured by 28‐day survival rates, of PMMA and AN69ST hemofilters in patients receiving CAH‐CRRT. METHODS: This retrospective observational study reviewed the medical records of 142 patients who received CAH‐CRRT between November 2013 and February 2015. RESULTS: The 28‐day survival rates were higher in the AN69ST group than in the PMMA group for patients with or without sepsis (all patients, 79.4% versus 54.1%; patients with sepsis, 77.3% versus 50.0%; patients without sepsis, 83.3% versus 57.5%; P < 0.05). No significant differences were observed regarding 28‐day survival rates of patients with or without sepsis (AN69ST, 77.3% versus 83.3%; P = 0.51; PMMA, 50.0% versus 57.5%; P = 0.61) using the same hemofilter. CONCLUSION: The AN69ST hemofilter could be more effective than PMMA hemofilters for improving the survival outcomes of patients with or without sepsis. John Wiley and Sons Inc. 2018-12-13 /pmc/articles/PMC6328921/ /pubmed/30651999 http://dx.doi.org/10.1002/ams2.382 Text en © 2018 The Authors. Acute Medicine & Surgery published by John Wiley & Sons Australia, Ltd on behalf of Japanese Association for Acute Medicine This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made. |
spellingShingle | Original Articles Kobashi, Shuichi Maruhashi, Takaaki Nakamura, Tomoya Hatabayashi, Erika Kon, Akihide The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study |
title | The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study |
title_full | The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study |
title_fullStr | The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study |
title_full_unstemmed | The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study |
title_short | The 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study |
title_sort | 28‐day survival rates of two cytokine‐adsorbing hemofilters for continuous renal replacement therapy: a single‐center retrospective comparative study |
topic | Original Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6328921/ https://www.ncbi.nlm.nih.gov/pubmed/30651999 http://dx.doi.org/10.1002/ams2.382 |
work_keys_str_mv | AT kobashishuichi the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT maruhashitakaaki the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT nakamuratomoya the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT hatabayashierika the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT konakihide the28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT kobashishuichi 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT maruhashitakaaki 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT nakamuratomoya 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT hatabayashierika 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy AT konakihide 28daysurvivalratesoftwocytokineadsorbinghemofiltersforcontinuousrenalreplacementtherapyasinglecenterretrospectivecomparativestudy |